CAROSELL Colon and Rectal cancer Opdivo Safety and Efficacy with 101
Research type
Research Study
Full title
A Phase Ib/ II Trial to Assess the Safety and Efficacy of CXD101 in Combination with the PD-1 Inhibitor Nivolumab in Patients with Metastatic, Previously-Treated, Microsatellite-Stable Colorectal Carcinoma
IRAS ID
241936
Contact name
Rachel Kerr
Contact email
Sponsor organisation
Celleron Therapeutics Ltd
Eudract number
2017-004509-42
Duration of Study in the UK
1 years, 6 months, 5 days
Research summary
The purpose of this study is to look at the effectiveness (how well the drug works) and safety of a new drug called CXD101 in combination with nivolumab (an established drug in certain cancers) in patients with a particular common form of colorectal (bowel) cancer, so called microsatellite-stable (MSS) colorectal cancer, that has spread and that cannot be removed by surgery. These two drugs may act together to stimulate the body’s own immune system to recognise, attack, and destroy cancer cells.
REC name
South Central - Oxford A Research Ethics Committee
REC reference
18/SC/0108
Date of REC Opinion
15 Apr 2018
REC opinion
Further Information Favourable Opinion